Media headlines about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tetraphase Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 44.8317282506427 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- This Morning’s Technical Outlook on Generic Drugs Stocks — Ironwood Pharma, Pacira Pharma, pSivida, and … – PR Newswire (press release) (prnewswire.com)
- Tetraphase Pharmaceuticals, Inc. (TTPH) stock price increased 16.36% from its 20-SMA – The Stocks News (press release) (thestocksnews.com)
- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Market Worth in Focus – Nasdaq Journal (nasdaqjournal.com)
- Technical Indicators should not be overlooked on Tetraphase Pharmaceuticals, Inc. (TTPH) – Wall Street Morning (wallstreetmorning.com)
- Tetraphase Pharmaceuticals to Present at 17th Annual Needham Healthcare Conference – GlobeNewswire (press release) (globenewswire.com)
Tetraphase Pharmaceuticals stock opened at $3.15 on Thursday. Tetraphase Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $9.93. The company has a market capitalization of $162.01, a PE ratio of -1.16 and a beta of 2.74.
Several equities analysts have commented on TTPH shares. SunTrust Banks reiterated a “buy” rating and issued a $10.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, February 14th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 12th. WBB Securities began coverage on Tetraphase Pharmaceuticals in a report on Thursday, February 22nd. They issued a “speculative buy” rating and a $6.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, December 5th. Finally, B. Riley assumed coverage on Tetraphase Pharmaceuticals in a research report on Monday, February 12th. They set a “buy” rating and a $11.00 target price on the stock. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $7.22.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $6.21, for a total transaction of $44,507.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.50% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.